SpecificiT (www.specificitpharma.com) is a biotech company spun out from our Minor Histocompatibility Antigens (MiHA) program led by Drs. Claude Perreault, Denis-Claude Roy and Jean-Sébastien Delisle form the Maisonneuve-Rosemont Hospital. SpecificiT is a clinical-stage company focused on developing cellular therapies for hematological cancers that are currently untreatable with chimeric antigen receptor modified T cells (CAR-T) therapies. The company’s unique approach directs unmodified donor T-cells at Minor Histocompatibility Antigens (“MiHAs”) to safely eliminate cancer cells in patients. In addition, the company is employing a proprietary platform to discover novel tumor neoantigens that would allow this unique immunotherapy approach to be used against solid tumors.